Bristol-Myers Squibb Co.

  • 3 Basic Reasons Medical Marijuana Stocks Are Doomed For Failure

    By Nickey Friedman - August 31, 2013 | Tickers: BMY, MDBX, MJNA, MRK, MYL, PFE

    We've all seen it. Medical marijuana stocks are flying into the stratosphere as a new industry in America is born. What's not to get excited about? There are only a handful of public companies breaking into this new, multi-billion dollar industry with high hopes and expectations of giant windfalls in profits for all. As this article explains, nobody needs to sell the industry -- it sells itself! It sells more »

  • 3 PDUFA Dates That Will Kickoff 2014

    By Brandy Betz - August 19, 2013 | Tickers: AZN, BMRN, BMY

    The phrase “PDUFA date” is thrown around frequently when discussing biotech and pharma companies. PDUFA stands for the Prescription Drug User Fee Act, which is a law allowing the Food and Drug Administration to charge companies that file new drug applications. The money goes towards expediting the review process that takes six months for drugs with an accelerated approval and ten months for a standard filing. Adding the appropriate number more »

  • A Small Cap Pharma Stock With Huge Growth Potentials

    By Naomi Warmate-Igwe - August 10, 2013 | Tickers: AVNR, BMY, CADX

    It is no longer news that a company’s earnings, including revenues and net income, usually play an important role in determining whether the company’s stock is headed up or down. Cadence Pharmaceuticals (NASDAQ: CADX) felt a bite of this simple truth when last week, it reported mixed quarterly earnings results. The report showed that the company beat analyst expectations in terms of revenues but when it came to more »

  • Buy These Leading Pharma Companies

    By Shweta Dubey - August 6, 2013 | Tickers: BMY, JNJ, PFE

    A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018. New patents and improvement in research and development will bolster companies’ portfolios, while a growing population and better access to healthcare will be key factors driving the market size for drugs. Pharmaceutical companies are working hard to capitalize on the growing market. Three such more »

  • These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff

    By Bob Ciura - August 2, 2013 | Tickers: BMY, LLY, PFE

    In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies. These stocks are widely bought for their blue chip status and hefty dividend yields. Investors likely feel peace of mind buying these stocks, as medicine and health care are fairly recession-proof.

    At the same time, the industry is at an important inflection point. Several big pharma companies are struggling with patent cliffs, which more »

  • This Biotech’s Cystic Fibrosis Treatments Could Catapult It To Profitability

    By Leo Sun - July 31, 2013 | Tickers: BMY, GILD, JNJ, VRTX

    Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle cell anemia. More than 30,000 Americans are currently diagnosed with CF, and an average of 1,000 new cases surface annually. One in 3,700 births is believed to have the defective CF gene, and it is estimated that more than more »

  • Don’t Miss These Leading Pharma Companies

    By Shweta Dubey - July 26, 2013 | Tickers: BMY, JNJ, PFE

    A recent EvaluatePharma report estimated the drug market of prescribed drugs to increase at CAGR of 3.8% to $895 billion between 2012-2018. New patents and improvement in research and development will be the key factors driving the market size of drugs. With the growth of drug market, pharmaceutical companies are in better position to monetize it. Three such pharmaceutical companies should be of interest to investors. These companies have more »

  • The Diabetes Pipeline With a Clog

    By Brandy Betz - July 22, 2013 | Tickers: AZN, BMY, LLY, JNJ

    Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and the partnership of Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). But the path to market proved tricky.

    Johnson and Johnson's Invokana earlier this year became the first SGLT2 approved in the United States. Bristol-Myers and AstraZeneca’s more »

  • Three Future Winners and One Major Loser in the HCV Wars

    By Leo Sun - July 18, 2013 | Tickers: ABBV, BMY, GILD, IDIX

    The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals. In my previous articles, I discussed treatments for cancer and diabetes, and how competition between major biotechs created increasingly innovative and effective treatments.

    Today I’d like to discuss another major disease - hepatitis C. The hepatitis C virus (HCV) affects an estimated 130-200 million people worldwide, and more »

  • A Fundamentally Strong Biotech Stock

    By Kanak Kanti - July 17, 2013 | Tickers: ABBV, BMY, CELG, ONXX

    Celgene (NASDAQ: CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial treatment for newly diagnosed multiple myeloma patients. This is indeed good news for the company after reports that Britain’s National Institute for Health and Care Excellence (NICE) may not recommend it for myelodysplastic syndromes in the U.K.

    Revlimid, Celegene’s more »

  • Could This Safe Play Help Eli Lilly?

    By Brandy Betz - July 11, 2013 | Tickers: BMY, LLY, GSK, NVO, SNY

    Note: This version has been amended to better reflect Victoza's dosage recommendations.

    At the American Diabetes Association meeting last month, Eli Lilly (NYSE: LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk (NYSE: NVO) and Bristol-Myers Squibb (NYSE: BMY).

    GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin more »

  • A Small-Cap Pharmaceutical Company With 2014 in Its Sights

    By Ashley Sales - July 5, 2013 | Tickers: AZN, BMY, MDCO

    A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ: MDCO). This stock is said to have strong catalysts that could lift the share price over the years. The company was at $20.40/share in November 2012 and is now trading at $31.60. The company has reported a 52-week high of $37.40.

    The biggest catalyst for a more »

  • Amgen vs. Big Pharma: It's Amgen for the Long Term

    By Nancy Tengler - July 1, 2013 | Tickers: AMGN, BMY, MRK

    Over the last three decades I have seen my share of bull and bear markets. And though no market cycle is exactly the same, there are eternal investing principles shareholders can depend upon like my Intelligent Investing Rule #1: Buy Great Companies for the Long-Term.  

    Buying big pharma and biotech stocks requires a long-term focus

    Large-cap pharmaceutical and biotechnology companies have performed relatively well over the last year but still more »

  • If You Are an Income Investor, You Will Love These Pharma Companies

    By Madhukar Dubey - June 30, 2013 | Tickers: BMY, GSK, MRK

    Companies know that to attract regular income-seeking investors, it helps to pay out high dividends. At times when treasuries are disappointing with low yields for 10-year T-notes and corporate bonds are offering no respite, the hunger for dividend stocks is higher than ever. Here are three companies in the pharmaceutical industry that are developing new drugs with high earnings potential in the long run. These companies are also generating ample more »

  • Is This What the Doctor Ordered for Eli Lilly?

    By Kanak Kanti - June 27, 2013 | Tickers: BMY, LLY, JNJ, MRK, NVO

    After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly (NYSE: LLY) finally has some good news to report. Releasing top-line results for its type II diabetes experimental drug dulaglutide, the company announced that patients taking the drug had manageable side effects, showed better blood sugar control, and lost more weight compared to existing drugs.

    If Lilly gains FDA approval for dulaglutide more »

  • Should You Buy Johnson & Johnson?

    By Bob Ciura - June 26, 2013 | Tickers: BMY, LLY, JNJ

    Stocks that stand the test of time are often ones that have a diversified product portfolio of world class brands. Companies such as these, whose products are purchased regardless of the prevailing economic climate, have the financial ability to weather any economic storm.

    Few companies have reached iconic stature as Johnson & Johnson (NYSE: JNJ) has over its many decades of dependability and stability.

    After a considerable rally over the past more »

  • Can't Anyone Tackle Alzheimer's?

    By Kanak Kanti - June 24, 2013 | Tickers: BAX, BMY, LLY, MRK, PFE

    After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly (NYSE: LLY), really has a foolproof plan to develop a useful treatment for Alzheimer’s. Although the companies discussed below are all great businesses, don't base your investment decisions on their Alzheimer's pipelines.

    Secretase inhibitors in very simple terms

    The science behind this approach to more »

  • The Diabetes Drug War

    By Robinson Roacho - June 19, 2013 | Tickers: BMY, LLY, SNY

    Technological advances have allowed for people to have more longevity. Drug companies research and develop medicines to prevent, control and cure diseases. Diabetes is a condition in which the levels of glucose increase above normal levels. This condition can be fatal if the glucose levels are not controlled. Eli Lilly (NYSE: LLY) and Sanofi (NYSE: SNY) are two major players that I believe will bring capital appreciation to their investors more »

  • The Best Healthcare Bet

    By Mohsin Saeed - June 18, 2013 | Tickers: ABT, BMY, GILD

    Gilead (NASDAQ: GILD) has been one of the most prolific investments in the healthcare sector. The company value has almost doubled in the last few years, and it continues to appreciate thanks to its stellar R&D. Gilead dominates the Hepatitis C Virus (HCV) treatment market, and the upcoming priority review of sofosbuvir can cement its HCV domination for years to come. It faces tough competition from Bristol Myers Squibb more »

  • Beware the Bullishness on Bristol-Myers

    By Bob Chandler - June 15, 2013 | Tickers: BMY, DNDN, MRK

    A new drug in the fight against cancer is certainly an exciting and welcome development. Unfortunately, in many cases, the news often pushes the stock price of the company involved to overly enthusiastic heights. While the optimism about the drug may be fully justified, some investor caution on the stock may be prudent.

    Recent news about Bristol-Myers Squibb's (NYSE: BMY) latest oncology drug candidate might be such a case more »

  • Page 1 of 10